Wednesday, 09 December 2015｜Source：CHINA CHAMBER OF COMMERCEFOR IMPORT&EXPORT OF MEDICINES &HEALTH PRODUCTS｜Author：
The 2nd BioPharm Innovation and Development Summit (hereinafter referred to as BioLink Summit), hosted by China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE), UBM Sinoexpo International Exhibition Co. Ltd, co-organized by The R&D-based Pharmaceutical Association Committee(RDPAC) was held in Beijing on December 1-2, 2015.
Known as the "sunrise industry" of the 21st century, bio-pharmaceutical industry has been a fast-growing global industry. Now that China has opened its window to the world, its biopharmaceutical industry will see more opportunities. By exploring China's market, presenting the progress of its biopharmaceutical industry and discussing the potential impact, BioLink Summit aims to bring new thoughts and ideas to China’s bio-pharma industry, improve the level in R&D and globalization of China’s biopharmaceutical companies.
More than 170 representatives attended the summit, including leading biopharmaceutical companies in China and in the world such as Johnson & Johnson Innovation, Bayer, Cardinal Health, BioCentury, Thomson Reuters, Ambrx, Accord Research, BeiGene, BGI, Hisun Pharmaceutical, Betta Pharmaceuticals, etc. , governments and agencies at home and abroad such as Chinese Pharmacopoeia Commission, US FDA’s China Office, USP-CHINA, etc. The BioLink Summit was formally opened on the morning of December 1. Dr. Ming Xu, Vice President of CCCMHPIE made the opening address. The topic of module 1 was “Industry Development and Updates on Regulatory Policies and Standards”. Joseph Cho, Managing Director of RDPAC, John Cai, Director of Center for Healthcare Management and Policy of CEIBS, Zhongping Guo, Director of Biological Standardization Department of Chinese Pharmacopoeia Commission, Dr. Trey Putnam, VP and GM of Regulatory Science of Cardinal Health and David Flores, CEO of Bio Century, Peter Janda, CEO of Accord Research, Chiang Syin, Associate Country Director of FDA’s China Office, Bingbing Feng, Vice President and General Manager of USP-CHINA, Zhou Feng, Product &Solution Specialist of Thomson Reuters delivered their speeches respectively. Dr. Mingde Xia, Senior Director of New Ventures of Johnson & Johnson Innovation acted as the chairman of the summit.
Three panel discussions were arranged in this summit, named Immune therapy and Precision Medicine, R&D and Production of Therapeutic Biologics and Biopharmaceuticals and Financing respectively. Meanwhile, Life Science Road Show for Financing and M&A, Life Science Technology Transfer Projects Road Show were also held during the the summit.
More about BioLink: apps.ubmasia.com/files/mediaobjects/Files/35/ashley/EN1026.html
Panel discussion：Biopharmaceuticals and Financing
Panel discussion： Immune therapy and Precision Medicine
More than 170 representatives attended the summit